Tagrisso and Dysstasia - a phase IV clinical study of FDA data

Summary:

Dysstasia is reported as a side effect among people who take Tagrisso (osimertinib mesylate), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Calcium, and have Lung neoplasm malignant.

The phase IV clinical study analyzes which people have Dysstasia when taking Tagrisso. It is created by eHealthMe based on reports of 19,861 people who have side effects when taking Tagrisso from the FDA, and is updated regularly.

What is Tagrisso?

Tagrisso has active ingredients of osimertinib mesylate. eHealthMe is studying from 19,890 Tagrisso users. Check the latest studies of Tagrisso.

What is Dysstasia?

Dysstasia (difficulty in standing) is found to be associated with 1,386 drugs and 1,369 conditions by eHealthMe. Check the latest studies of Dysstasia.

On Jul, 16, 2026

19,861 people reported to have side effects when taking Tagrisso.
Among them, 15 people (0.08%) have Dysstasia.

Among these 15 people:

How long have people been on Tagrisso when they have Dysstasia? *

What is the gender of people who have Dysstasia when taking Tagrisso? *

female: 66.67 %
male: 33.33 %

What is the age of people who have Dysstasia when taking Tagrisso? *

What are other drugs people take besides Tagrisso? *

What are other side effects people have besides Dysstasia? *

Weakness: 5 people, 33.33%
Dizziness: 4 people, 26.67%
Fall: 4 people, 26.67%
Weight Decreased: 3 people, 20.00%
Constipation: 3 people, 20.00%
Death: 3 people, 20.00%
Diarrhea: 3 people, 20.00%
Dyspnea (difficult or laboured breathing): 3 people, 20.00%
Fatigue (feeling of tiredness): 3 people, 20.00%
Feeling Abnormal: 3 people, 20.00%

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 7 people, 46.67%
Lung Cancer - Non-Small Cell (lung cancer): 4 people, 26.67%
Thrombocytosis: 1 person, 6.67%
Thrombocytopenia (decrease of platelets in blood): 1 person, 6.67%
Pulmonary Mass: 1 person, 6.67%
Pulmonary Embolism (blockage of the main artery of the lung): 1 person, 6.67%
Lung Carcinoma Cell Type Unspecified Stage Iv (the lung cancer has spread to other organs of the body, such as the other lung, brain, or liver): 1 person, 6.67%
Lung Carcinoma Cell Type Unspecified Stage 0 (the lung cancer has not spread beyond the inner lining of the lung): 1 person, 6.67%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 1 person, 6.67%
Bone Disorder: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Tagrisso and have Dysstasia?

- Check whether Dysstasia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tagrisso:

Tagrisso (19,890 reports)

Dysstasia treatments and more:

Dysstasia (35,077 reports)

Browse all side effects of Tagrisso:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dysstasia:

Dysstasia (1,387 drugs)

Browse all the conditions that are associated with Dysstasia:

Dysstasia (1,369 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on osimertinib mesylate (the active ingredients of Tagrisso) and Tagrisso (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.